Apollomics Inc.
APLM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APLM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APLM
Apollomics Inc. is a pre-revenue biotechnology company focused on developing oncology therapies, with its most advanced candidate vebreltinib still in clinical development and no approved products.
Key risk: Dependence on vebreltinib
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2024.
Tracking 4 clinical trials for Apollomics Inc..
Apollomics Inc. is a pre-revenue biotechnology company focused on developing oncology therapies, with its most advanced candidate vebreltinib still in clinical development and no approved products.
- Apollomics has no approved products and is dependent on the success of vebreltinib, its most advanced product candidate [sec · filed 2026-04-24].
- The company reported cash & equivalents of $9.8M as of 2024-12-31, with no revenue and a net loss of $53.9M for that period [sec].
- For the year ended December 31, 2025, Apollomics had net losses of $10.9M and used $10.4M in net cash for operations [sec · filed 2026-04-24].
- The company has built a network of clinical trial centers across more than ten jurisdictions, including the U.S., China, Canada, and Europe [sec · filed 2026-04-24].
- Apollomics plans to seek strategic partnerships to optimize efficiency and maximize market potential of its assets [sec · filed 2026-04-24].
What works
- Apollomics has established a global clinical trial network across more than ten jurisdictions, which may facilitate patient recruitment and regulatory submissions [sec · filed 2026-04-24].
- The company has adopted a biomarker-driven diagnostic approach for patient screening, potentially increasing the likelihood of clinical trial success [sec · filed 2026-04-24].
- In the third quarter of 2025, Apollomics appointed a new executive management team with expertise in corporate restructuring, global clinical operations, and capital markets [sec · filed 2026-04-24].
What to weigh
- Apollomics has incurred losses in each period since inception and expects to continue incurring net losses for the foreseeable future [sec · filed 2026-04-24].
- The company is substantially dependent on the success of vebreltinib, its most advanced product candidate, which is still in clinical development [sec · filed 2026-04-24].
- Apollomics has no track record in launching and marketing any commercial products, and its ability to generate revenue is uncertain [sec · filed 2026-04-24].
- The company may need to raise additional capital, which could cause dilution to shareholders and restrict operations [sec · filed 2026-04-24].
From the filings
Quoted directly from source documents.
Apollomics has no approved products and depends on vebreltinib.
“We are substantially dependent on the success of vebreltinib, our most advanced product candidate.”
SEC filings · April 24, 2026
Apollomics reported net losses of $10.9M for the year ended December 31, 2025.
“For the year ended December 31, 2025 we had net losses of $10.9 million and we used $10.4 million in net cash for operat”
SEC filings · April 24, 2026
Apollomics has built a global clinical trial network.
“We have built a network of centers for clinical trials across more than ten jurisdictions, including the United States, China, Canada, England, France, Spain, Germany, Italy, Australia, Taiwan and Singapore”
SEC filings · April 24, 2026
Apollomics has no track record in commercial sales.
“We have no track record in launching and marketing any commercial products.”
SEC filings · April 24, 2026
Risks & what to watch (4)›
Key risks
- Dependence on vebreltinib — Apollomics is substantially dependent on the success of vebreltinib, its most advanced product candidate, which is still in clinical development [sec · filed 2026-04-24].
- History of losses and cash burn — The company has incurred losses since inception and used $10.4M in net cash for operations in 2025, with cash of $9.8M as of 2024-12-31 [sec · filed 2026-04-24].
- No approved products or revenue — Apollomics has no products approved for commercial sale and no track record in marketing, making future revenue uncertain [sec · filed 2026-04-24].
- Need for additional financing — The company may need to raise additional capital, which could cause dilution and restrict operations [sec · filed 2026-04-24].
What to watch
- Clinical trial results for vebreltinib, the most advanced product candidate [sec · filed 2026-04-24].
- Ability to secure strategic partnerships for development and commercialization [sec · filed 2026-04-24].
- Cash runway and potential need for additional financing given cash of $9.8M as of 2024-12-31 [sec].
- Regulatory progress and any updates on approval applications for pipeline candidates [sec · filed 2026-04-24].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Apollomics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apollomics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.0 months
D/E 1.69
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$7K
| Holder | Shares | Value |
|---|---|---|
| citigroup inc | 438 | $7K |
| blackrock, inc. | 1 | $16 |
Short Interest
as of May 20, 2026- % of float
- 0.2%
- Days to cover
- 0.3
- Shares short
- 2,692
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APLM short interestFrequently asked questions
What is the AI investment thesis for Apollomics Inc.?
Apollomics Inc. is a pre-revenue biotechnology company focused on developing oncology therapies, with its most advanced candidate vebreltinib still in clinical development and no approved products.
Who is the CEO of Apollomics Inc.?
Mr. Hung-Wen Chen is the chief executive officer of Apollomics Inc. (APLM).
Where is Apollomics Inc. headquartered?
Apollomics Inc. (APLM) is headquartered in Foster City, CA, United States.
What therapeutic areas does Apollomics Inc. focus on?
Apollomics Inc. develops therapies across Oncology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.